Tests:Carcinoembryonic Antigen: Difference between revisions
- Department
- Biochemistry
Tests:Carcinoembryonic Antigen
No edit summary |
No edit summary |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 5: | Line 5: | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Overview == | ||
|- | |- | ||
|Department | |Department | ||
| Line 15: | Line 15: | ||
|Synonyms | |Synonyms | ||
|CEA | |CEA | ||
|- | |||
|Availability | |||
|Monday - Friday | |||
Contact the lab if urgent testing is required | |||
|- | |- | ||
|Turnaround Time | |Turnaround Time | ||
| Line 23: | Line 27: | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Specimen Requirements == | ||
|- | |- | ||
|Specimen | |Specimen | ||
|Serum | |Serum | ||
|- | |- | ||
|Preferred | |Preferred | ||
| | |<span style="background: #fbec5d">Yellow-Top</span> or <span style="background:#e30022"> Red-Top </span> tube | ||
|- | |- | ||
|Acceptable | |Acceptable | ||
| | | | ||
|- | |||
|Unacceptable | |||
|Plasma | |||
|- | |- | ||
|Specimen Transportation | |Specimen Transportation | ||
| | | | ||
|- | |- | ||
| | |Paediatric Requirements | ||
| | |0.5 mL blood in <span style="background:#e30022"> Red-Top </span> tube | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Aliquot Requirements == | ||
|- | |- | ||
|Sample | |Sample | ||
|Serum | |Serum | ||
|- | |||
|Preferred Volume | |||
|0.5 mL | |||
|- | |- | ||
|Minimum Volume | |Minimum Volume | ||
|100 | |100 µL | ||
|- | |- | ||
|Aliquot Transportation | |Aliquot Transportation | ||
| Line 55: | Line 63: | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== Clinical Information == | |||
|- | |- | ||
|Reference Intervals | |Reference Intervals | ||
|0.0 - 5.0 | |0.0 - 5.0 µg/L | ||
|- | |- | ||
|Test Method | |Test Method | ||
|Abbott Alinity | |Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. | ||
|- | |- | ||
|Advanced Notice | |Advanced Notice | ||
| Line 70: | Line 78: | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Comments == | ||
|- | |- | ||
| colspan="2" |CEA is a marker for colorectal, gastrointestinal, lung and breast carcinomas. | | colspan="2" |CEA is a marker for colorectal, gastrointestinal, lung and breast carcinomas. | ||
| Line 82: | Line 90: | ||
For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | ||
|} | |} | ||
{{DocMeta | |||
| owner = Crossley1 | |||
| review_ping = | |||
}} | |||
<!-- review-ping: 2026-09-14T08:08:59.777Z --> | |||
Latest revision as of 21:37, 23 September 2026
Overview | |
|---|---|
| Department | Biochemistry |
| Test Code | TCEA |
| Synonyms | CEA |
| Availability | Monday - Friday
Contact the lab if urgent testing is required |
| Turnaround Time | 2 hours – 3 days |
| Stability – Add test | 24 hours |
Specimen Requirements | |
| Specimen | Serum |
| Preferred | Yellow-Top or Red-Top tube |
| Acceptable | |
| Unacceptable | Plasma |
| Specimen Transportation | |
| Paediatric Requirements | 0.5 mL blood in Red-Top tube |
Aliquot Requirements | |
| Sample | Serum |
| Preferred Volume | 0.5 mL |
| Minimum Volume | 100 µL |
| Aliquot Transportation | |
Clinical Information | |
| Reference Intervals | 0.0 - 5.0 µg/L |
| Test Method | Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. |
| Advanced Notice | Not required |
| Patient Preparation | Not required |
Comments | |
| CEA is a marker for colorectal, gastrointestinal, lung and breast carcinomas.
CEA levels are not an absolute test for evidence of malignancy and must be used in conjunction with the clinical evaluation of the patient and other diagnostic evidence. Healthy non-smokers have CEA levels less than 3.0 µg/mL, while 6% of otherwise healthy smokers have CEA levels up to 5.0 µg/mL. CEA is not suitable as a screening test for the primary diagnosis of tumours. For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | |
| Owner | Clair Crossley (Crossley1) |
|---|---|
| Last reviewed | 23 Sep 2026 |
| Next review | 23 Sep 2027 OK |